SA PRO
Free Account
Nurix Therapeutics, Inc.NRIXNASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
17 analysts·Moderate coverage
100%
Rating Distribution
Strong Buy
00%
Buy
17100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 86% higher.

Bear Case
$28.00
+67%
Consensus
$31.22
+86%
Bull Case
$36.00
+114%
Price Range17 analysts
Low
Consensus
High
$28.00
$36.00
Current Target
Current Price
$16.79
Upside to Target
$14.43

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.12(12 analysts)
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+23.91%
EPS—
FY2028
Rev+56.71%
EPS—
FY2029
Rev+115.48%
EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)
Avg surprise:-0.4%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 29, 2026Stifel Nicolaus
Nurix Therapeutics price target raised to $35 from $33 at Stifel
Target:$35.00
+88.6%from $18.55
Jan 29, 2026Wells Fargo
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
Target:$29.00
+62.3%from $17.87
Jan 29, 2026H.C. Wainwright
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
Target:$32.00
+79.1%from $17.87
Jan 8, 2026Morgan Stanley
Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
Target:$36.00
+94.7%from $18.49
Dec 10, 2025H.C. Wainwright
Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright
Target:$31.00
+58.6%from $19.55
Dec 9, 2025BTIG
Nurix Therapeutics price target raised to $30 from $27 at BTIG
Target:$30.00
+39.7%from $21.47
Nov 24, 2025Truist Financial
Nurix Therapeutics assumed with a Buy at Truist
Target:$30.00
+74.7%from $17.18
Oct 28, 2025H.C. Wainwright
Nurix Therapeutics price target lowered to $28 from $33 at H.C. Wainwright
Target:$28.00
+134.6%from $11.93
Oct 23, 2025BTIG
Nurix Therapeutics price target lowered to $27 from $35 at BTIG
Target:$27.00
+154.0%from $10.63
Oct 23, 2025Wells Fargo
Nurix Therapeutics price target lowered to $21 from $22 at Wells Fargo
Target:$21.00
+100.7%from $10.47
Oct 22, 2025RBC Capital
Nurix Therapeutics price target raised to $29 from $28 at RBC Capital
Target:$29.00
+172.8%from $10.63
Oct 14, 2025H.C. Wainwright
Nurix Therapeutics price target lowered to $33 from $34 at H.C. Wainwright
Target:$33.00
+239.5%from $9.72
Oct 13, 2025Wells Fargo
Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
Target:$22.00
+125.4%from $9.76
Oct 10, 2025Stifel Nicolaus
Nurix Therapeutics price target lowered to $33 from $35 at Stifel
Target:$33.00
+238.1%from $9.76
Oct 10, 2025Oppenheimer
Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer
Target:$28.00
+157.8%from $10.86
Oct 10, 2025Piper Sandler
Nurix Therapeutics price target lowered to $32 from $35 at Piper Sandler
Target:$32.00
+194.7%from $10.86
Jul 15, 2025Morgan Stanley
Nurix Therapeutics price target lowered to $16 from $17 at Morgan Stanley
Target:$16.00
+26.1%from $12.69
Jul 10, 2025Oppenheimer
Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer
Target:$30.00
+136.8%from $12.67
Mar 17, 2025Leerink Partners
Nurix Therapeutics initiated with a Market Perform at Leerink
Target:$16.00
+14.9%from $13.93
Feb 3, 2025Morgan Stanley
Nurix Therapeutics price target raised to $17 from $16 at Morgan Stanley
Target:$17.00
-10.3%from $18.95
Dec 5, 2024BMO Capital
BMO Capital Starts Nurix (NRIX) at Outperform
Target:$35.00
+74.5%from $20.06
Oct 24, 2024UBS
UBS Starts Nurix (NRIX) at Buy
Target:$35.00
+41.2%from $24.78
Oct 21, 2024H.C. Wainwright
Nurix (NRIX) PT Raised to $30 at H.C. Wainwright
Target:$30.00
+19.1%from $25.19
Oct 15, 2024Oppenheimer
Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
Target:$35.00
+40.7%from $24.87
Oct 15, 2024Wells Fargo
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
Target:$32.00
+27.2%from $25.16

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance